

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
University of Missouri	03/24/2005
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10854533
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director, DEITR, NIH
Total Attachments: 1 source=10854533-p0001 - p0003#page3.tif	

REC'D APR 04 2005

LICENSE TO THE UNITED STATES GOVERNMENT


This instrument confers to the United States Government, as represented by the National Institutes of Health, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention:

Invention Title: "New Antiviral Agents for the treatment of Epithelial/Stromal Keratitis"
Inventor(s): Ashim Mitra
U.S. Patent Application
Serial No.: 10/854,533
File Date: May 26, 2004
Patent Number:
Title: "Acyclovir-Peptide Analogs"
Country, if other
than United States:


This subject invention was conceived or first actually reduced to practice in performance of a government-funded project, NIH Grant No. 5 R01 EY09171-07 and NIH Grant No. 5 R01 EY10659-06.

Principal rights to this subject invention have been left with the Licensor: The Curators of the University of Missouri, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed:



Date:



Typed Name: Thomas R. Sharpe, Ph.D.

Title: Executive Director, Office of Technology & Special Projects